New to shockwave or in pain for more than 3 months? Book a Telehealth to see if we can help you!
Hip osteoarthritis (OA) is a degenerative joint condition that causes chronic hip pain, stiffness, and reduced mobility. Standard treatments like exercise, physical therapy, pain medications (NSAIDs), or cortisone injections often provide only partial relief, and severe cases may eventually require total hip replacement. In recent years, extracorporeal shockwave therapy (ESWT) – a non-surgical treatment using targeted acoustic waves – has emerged as a potential therapy to stimulate healing in musculoskeletal tissues. Unlike painkillers or steroid injections that mainly mask symptoms, shockwave therapy aims to “stimulate real healing by breaking down scar tissue, increasing blood flow, and triggering collagen production” in the affected joint. This has raised interest in whether shockwave therapy can reduce hip OA pain and improve function. Below, we examine the most up-to-date scientific evidence (from roughly the past 5–10 years) on shockwave therapy for hip OA. We also draw on high-quality research in similar weight-bearing joints (especially knee OA, since studies on hip OA are still limited) and insights from the Unpain Clinic’s own podcast and videos on shockwave treatment for hip pain.
Research specifically focusing on shockwave therapy for hip OA in humans is relatively new. In fact, the first randomized controlled trial (RCT) in the literature to evaluate ESWT for hip osteoarthritis was published in late 2022. In this 2022 pilot study (Volkan Şah et al., J. Pers. Med. 2023), 148 patients with hip OA were randomly assigned to receive focused ESWT, radial ESWT, or a sham (placebo) treatment. Each patient received a series of shockwave sessions over 4 weeks, and outcomes were measured at the end of treatment (4 weeks) and one month later (8 weeks). The findings were encouraging:
Both focused and radial shockwave therapy groups showed significant reductions in pain (measured by Visual Analog Scale, VAS) and improvements in hip function (measured by the WOMAC osteoarthritis index) at 4 and 8 weeks compared to baseline (p < 0.001). In contrast, the sham group showed no such improvements, indicating the shockwave effect was beyond placebo.
Focused shockwaves performed better than radial: the focused ESWT group had greater decreases in VAS pain scores and WOMAC disability scores than the radial group at both 4 and 8 weeks (the between-group difference was statistically significant, p < 0.002). Both types of ESWT, however, were superior to sham in terms of treatment efficacy.
This RCT concluded that ESWT can effectively relieve pain and improve short-term function in hip OA, with focused shockwaves potentially providing stronger benefits than radial shockwaves. As a pilot trial, it provides initial proof-of-concept that shockwave therapy is a promising non-invasive option for hip OA patients who need better pain relief and joint function.
Aside from this human trial, it’s worth noting that earlier investigations were scarce – one veterinary study in dogs with hip OA showed radial shockwaves improved limb function, but no human studies on hip OA had been published prior to 2022. The hip joint has thus lagged behind other joints (like the knee) in shockwave research. Given this limited direct evidence, we turn to high-quality studies on knee osteoarthritis, a weight-bearing joint with similar cartilage degeneration issues, to infer how shockwave therapy might translate to the hip. (We will also clearly note that knee findings may not fully generalize to the hip, but they offer the best insights until more hip-specific studies are done.)
Shockwave therapy has been studied more extensively for knee OA, with several randomized trials and systematic reviews in the past few years. These studies consistently show that ESWT can reduce knee pain and improve physical function in the short to medium term:
Systematic Review & Meta-Analysis (2020, Int. J. Surgery) – 14 RCTs: A comprehensive 2020 meta-analysis pooled data from 14 randomized trials (782 patients) with knee OA and found moderate-quality evidence that ESWT yields significant improvements in both pain and function. On average, shockwave therapy reduced pain scores by about 1.7 cm on a 10-cm VAS and improved WOMAC (a joint pain/stiffness/function index) by ~14 points more than control treatments. These are clinically meaningful improvements in osteoarthritis symptoms. Intriguingly, this review also noted that the dosage of shockwaves matters – intermediate-energy shockwave settings produced better outcomes on pain and WOMAC than either low- or high-energy settings. This suggests there may be an optimal energy dose for treating osteoarthritic joints. The authors concluded that ESWT is a safe and effective therapy for knee OA in the short term, although most trials only tracked patients for a few months. Minor side effects (temporary soreness, etc.) were reported, but no serious adverse events. They recommended further research with longer follow-ups and standardized protocols.
Systematic Review & Meta-Analysis (2020, Pain Medicine) – 8 RCTs: Another review published in 2020 looked at shockwave vs. control in knee OA and specifically examined longer-term outcomes. It found that pain relief from ESWT persisted through 6 and 12 months after treatment, based on pooled WOMAC and VAS scores. Physical function (the ability to move and perform activities) was also significantly better in the ESWT group than control at 6- and 12-month follow-ups. In other words, patients who received shockwave therapy maintained improvements in pain and walking ability for up to a year. Only minor complications were observed (no serious complications). The review did highlight an important gap: there isn’t yet a clear consensus on the optimal treatment frequency and number of sessions needed to maximize these benefits. Different trials used varying protocols (some used 3–5 sessions, once weekly, others different energy levels), making it hard to know the ideal regimen. Nonetheless, the take-home message was that ESWT provides meaningful pain and function improvements for knee OA that can last at least 1 year, without significant safety concerns.
Randomized Controlled Trials: Individual RCTs on knee OA reinforce these findings. For example, a 2019 double-blind RCT (Zhong et al., Arch. Phys. Med. Rehabil. 2019) tested low-dose focused shockwave vs. sham in 63 patients with mild-moderate knee OA. After 4 weekly treatments, the shockwave group had significantly greater pain reduction and functional gains than the placebo group at both 5 weeks and 12 weeks follow-up. Knee pain scores (VAS), WOMAC function scores, and even a clinical mobility test (Lequesne index) all improved more with ESWT than with sham. Both groups did some home exercise, but only the shockwave group saw these superior outcomes. There were no serious side effects – minor aches occurred at similar rates in both groups. Interestingly, this trial also did MRI scans of the knee cartilage (T2 mapping) to see if shockwaves affected the joint tissue. They observed no significant cartilage differences between groups during the study, although the ESWT group showed a slight increase in T2 values at 12 weeks (the authors noted this could indicate some transient cartilage edema or “change,” but its clinical significance was unclear). Importantly, the symptom improvements did not come at the cost of visible cartilage damage on MRI, and patients felt better. The authors concluded that 4 sessions of shockwave therapy were superior to placebo for easing pain and improving knee function in OA, at least over a 3-month period. (They also cautioned that more research is needed on long-term cartilage effects, but so far the evidence of harm is minimal.)
Shockwave vs. Other Therapies: Shockwave has also been directly compared to other common treatments for knee OA in various studies. A 2020 meta-analysis by Chen et al. examined ESWT against a range of comparators (including exercise, injections, and traditional therapies). They found shockwave therapy led to significantly greater pain reduction and functional improvement than placebo, corticosteroid injections, hyaluronic acid injections, oral medications, or therapeutic ultrasound in patients with OA (p < 0.05 for all). In those comparisons, shockwave often outperformed the standard care – for instance, patients receiving ESWT reported lower pain and disability scores than those who got steroid or gel injections. Similarly, shockwave showed better functional outcomes than a standard exercise (kinesiotherapy) program alone. On the other hand, when shockwave was compared to a few more advanced or niche therapies, the differences were less stark: shockwave was about equivalent to manual therapy (no significant difference in outcomes vs. hands-on manipulation) and similar to acupotomy (a minimally invasive needling procedure). Compared to platelet-rich plasma (PRP) injections, shockwave produced better pain relief but similar functional results. These nuanced findings suggest that while shockwave tends to outperform passive modalities and injections in relieving OA symptoms, it may be on par with some other physical therapy modalities or regenerative techniques for certain outcome measures. Notably, across all these trials, no serious adverse reactions were reported – shockwave’s safety profile was consistently good. The upshot is that shockwave therapy is a valid conservative treatment for osteoarthritis, with evidence of efficacy against pain and stiffness comparable or superior to many standard treatments. Experts have started to recommend ESWT as an option, particularly for patients with knee OA who don’t respond to basics like exercise or who want to delay surgery.
Quality of Life Improvements: Beyond pain and physical function, some studies have assessed quality of life in OA patients receiving shockwave therapy. A new 2025 randomized study in Turkey compared ESWT to low-level laser therapy and pulsed electromagnetic field therapy for knee OA (with all groups doing rehab exercises as well). All active treatments improved patients’ SF-36 quality-of-life scores along with reducing pain and improving function over 3 months. Notably, shockwave (and laser) yielded greater gains in the SF-36 physical functioning domain than the electromagnetic therapy. The authors concluded that in the short term, shockwave therapy effectively reduces knee pain, improves physical function, and enhances health-related quality of life for knee OA patients. This quality-of-life benefit makes sense – by decreasing pain and increasing mobility, shockwave can help people return to daily activities, which boosts overall well-being.
Limitations: While knee OA findings are encouraging and biologically relevant to hip OA, we must acknowledge that the hip is not identical to the knee. The hip joint is deeper, with thick surrounding muscles, and shockwave application techniques may differ. The optimal energy settings or number of sessions for a hip may not be exactly the same as for a knee. Also, the pattern of cartilage degeneration differs (hip OA often involves the femoral head and acetabulum vs. tibiofemoral joint in knee). Therefore, we use knee data to guide expectations, but direct evidence in hip OA remains needed. The 2022 pilot hip study is a start, and it mirrored the knee studies in showing short-term pain/function improvement with shockwaves. Until larger hip-specific trials confirm these benefits for longer periods, clinicians will cautiously extrapolate from knee evidence when treating hip OA.
Synthesizing the research above, here are the key outcomes that shockwave therapy has demonstrated in osteoarthritis of weight-bearing joints:
Pain Reduction: Almost all studies report that ESWT leads to a significant reduction in pain levels. Patients typically experience decreases in their VAS pain scores and WOMAC pain sub-scores. For example, knee OA patients treated with shockwaves had about a 17–20% greater pain reduction than controls on average. In hip OA, the pilot RCT showed marked VAS pain score drops within 4–8 weeks of ESWT. Some patients feel improvement within a few treatments, though maximal pain relief may take several weeks as the healing processes kick in. Notably, in a comparison with steroid injections for lateral hip pain (trochanteric bursitis, often related to hip OA), shockwave’s pain-relief was more sustained: a study found that at 4 months and 15 months post-treatment, shockwave patients reported less hip pain than those who got a cortisone shot, even though the injection worked faster in the first few weeks. This suggests shockwave therapy may provide longer-term analgesic benefits by addressing tissue healing, whereas injections provide short-term inflammation control.
Improved Physical Function: Shockwave therapy consistently yields functional improvements – patients can walk farther, move with less stiffness, and perform daily tasks more easily. WOMAC function scores and timed get-up-and-go tests improve significantly after ESWT. In knee OA meta-analyses, functional indices improved in the shockwave groups by a meaningful margin (e.g. ~14 points better WOMAC, which covers pain, stiffness, and function). Focused ESWT has even been shown to increase knee range-of-motion by ~17° more than sham in one analysis. In hip OA, the 2022 trial noted better WOMAC function scores (which include activities like stair climbing, putting on socks, etc.) after shockwave treatment. Restoring function is crucial for quality of life – patients report being able to walk longer, climb stairs or carry out exercises with less difficulty after a course of shockwaves. In one trial on chronic hip bursitis, even individuals who initially didn’t improve with exercise therapy were able to regain strength and function once they received shockwave therapy, underscoring that ESWT can jump-start rehabilitation when exercise alone isn’t enough.
Quality of Life Gains: Reduction in pain and better mobility translate to better quality of life. Studies using the SF-36 survey have documented improvements in physical role functioning and vitality after shockwave therapy for knee OA. Patients often report sleeping better (less night pain), returning to hobbies, or simply feeling more independent in daily activities following ESWT. One recent clinical investigation found shockwave therapy significantly enhanced SF-36 physical function scores in knee OA patients at 3 months compared to baseline. Even though “quality of life” is a broad outcome, it is encouraging that shockwave’s benefits extend beyond clinical scores to how patients feel and live day-to-day. In the words of one patient treated at Unpain Clinic (from a YouTube testimonial), shockwave was “life-changing,” allowing them to resume normal life after suffering chronic hip and back pain for years. While individual experiences vary, the ability of ESWT to address the root problem (poor tissue healing) means the improvements tend to last and support long-term well-being, rather than just giving a fleeting placebo boost.
Duration of Effects: How long do the benefits last? Short-term follow-ups (1–3 months) uniformly show pain and function improvement with ESWT. For longer term, evidence is still emerging. The knee studies indicate that many patients maintain better pain and function at 6 months and even 1 year post-treatment. For example, Wang et al. reported significantly lower pain scores in the ESWT group versus controls at 12 months. However, not everyone maintains full benefit; some patients might experience pain creeping back over time, especially if underlying degeneration progresses. The encouraging aspect is that shockwave therapy can be repeated or used as needed – it is non-invasive and can be safely re-administered if symptoms return. Some practitioners schedule “booster” sessions a few months later for tough cases. In comparison to steroid injections (which often wear off in 2–3 months and can’t be repeated too frequently due to side effects), shockwave offers a more durable solution for many patients, addressing not just inflammation but tissue healing. In chronic greater trochanteric pain (lateral hip), for instance, one study saw an 86% success rate at 2 months with focused shockwave plus exercise, and MRI evidence of tendon healing accompanying the clinical improvement. Such findings give hope that with the right treatment plan, shockwave’s benefits for hip OA could also endure over the long run – though this needs confirmation from dedicated hip studies with 6–12 month follow-ups.
Like any treatment, individual responses to shockwave therapy can vary. Clinicians and researchers have observed a few factors that influence outcomes:
Severity and Chronicity of Condition: Patients with long-standing, severe degeneration (e.g. advanced hip OA or extensive tendon damage) may respond more slowly or require more sessions. In the context of lateral hip pain, those with significant gluteal tendon degeneration needed extra treatments or occasional maintenance sessions to keep pain at bay. In contrast, someone with a fresher injury or milder OA might notice improvements faster – sometimes even after 1–2 sessions – since their capacity for healing is greater. Essentially, the more chronic and fibrotic the tissue, the more “wake-up calls” it might need via shockwaves.
Patient Age and Health: Older patients or those with comorbidities (like diabetes or poor circulation) tend to heal more slowly in general. These individuals might not experience as dramatic a response, or they might require a higher number of shockwave treatments over a longer period to achieve the same effect. On the other hand, younger or healthier patients often have more robust regenerative capacity – shockwave therapy can leverage their body’s healing mechanisms more effectively, leading to quicker relief. For example, a person in their 40s with early OA might respond more readily than someone in their 70s with advanced OA, simply due to differences in tissue vitality. That said, even older patients see benefit; they just may progress more gradually.
Shockwave Dosage and Technique: The energy level, frequency, and focus (radial vs. focused) of shockwaves can influence outcomes. As noted earlier, medium-energy shockwaves appeared to yield better pain relief than very low or very high energies in one meta-analysis. Too low energy might be insufficient stimulus, whereas too high could cause more tissue stress without added benefit. Focused shockwave devices can penetrate deeper (useful for deep hip joint or gluteal tendon targets), while radial devices cover a broader area superficially. The 2022 hip OA trial suggests focused ESWT might be more effective for deep joint pain than radial ESWT – likely because the hip is a deep joint surrounded by thick soft tissue, favoring an energy concentration at depth. Clinically, many therapists combine both: using focused ESWT for deep structures (e.g. hip joint capsule or insertion of deep muscles) and radial ESWT for superficial soft tissues (e.g. iliotibial band or peri-hip muscle trigger points). Finding the right protocol (number of pulses, intensity, sessions/week) is part of individualized care. It’s worth noting that research hasn’t yet pinpointed the perfect protocol – studies have used anywhere from 3 to 6 sessions, once or twice weekly, with varying energy flux densities. If one approach isn’t yielding results by mid-therapy, providers might adjust energy or target spots (for example, increase intensity or treat a different contributing structure).
Concomitant Treatments: Shockwave is often integrated into a broader rehab program. Patients who also engage in exercise therapy, stretching, and strengthening tend to consolidate the gains from shockwave. For instance, shockwave might reduce pain enough to allow a patient to perform exercises that rebuild muscle support for the hip. Those who follow through with home exercises and address biomechanical issues often have better long-term outcomes than those who rely on shockwave alone. This is why some trials combine ESWT with exercise and find excellent results (as in the GTPS study with 86% success when both were used). On the flip side, if a patient has uncorrected issues (e.g. leg length discrepancy, gait abnormality, or an untreated adjacent joint problem), they might get pain relief from shockwaves, but the underlying stress continues and could limit the extent of improvement. The key is a comprehensive approach – shockwave to jump-start healing, plus therapy to fix contributory factors – which maximizes the chance of success.
The good news is that when shockwave therapy works, its effects tend to be long-lasting because it aims to actually improve tissue health (through collagen synthesis, new blood vessel formation, etc.) rather than just numbing the pain. Roughly three out of four patients with chronic hip-region pain (like trochanteric bursitis) appear to get significant relief from shockwave treatment. This means there is still a subset (perhaps 20–25%) who may not respond sufficiently – those could be cases of extremely advanced joint destruction or factors not amenable to shockwave (e.g. pain driven by severe bone-on-bone arthritis). Identifying predictors of response is an area for future research. For now, clinicians often undertake a trial of a few sessions and look for early signs of improvement; if none are seen, the therapy can be reconsidered. Fortunately, for many patients shockwave can be the “missing piece” – a therapy that finally triggers improvement after other treatments failed.
One of the attractive features of shockwave therapy is its strong safety profile. Unlike surgery or long-term medications, ESWT does not carry serious systemic risks. Key points on safety from the studies and clinical reports include:
Non-Invasive and Low Risk: Shockwave therapy involves no incisions or injections – the treatment is applied externally over the skin. There’s no need for anesthesia in most cases. Patients can typically walk in and walk out the same day, as there’s no downtime or recovery period needed. This makes ESWT especially appealing for older adults who may not tolerate surgery or for those looking to avoid opioid pain medications.
Common Side Effects: The most commonly reported side effects are mild and short-lived. Patients might experience soreness, redness, or mild bruising at the treatment site, usually lasting a day or two. This is comparable to feeling a bit tender after a deep-tissue massage or a strenuous workout – essentially a sign that the tissues have been stimulated. In clinical trials, these local side effects have been transient and resolved on their own. During the treatment itself, the sensation can be uncomfortable – often described as an intense tapping or throbbing sensation – but therapists can adjust the intensity to keep it tolerable. Most patients acclimate to the feeling after a few minutes, and importantly any procedure-related discomfort stops immediately when the treatment ends.
No Serious Adverse Events: Across numerous studies on musculoskeletal conditions, no serious or lasting complications have been reported with therapeutic shockwave use. A 2021 review covering hundreds of patients treated with shockwave for various orthopedic issues noted zero serious adverse effects. Unlike certain drug treatments, ESWT doesn’t cause internal organ side effects, and unlike steroid injections, it doesn’t carry a risk of accelerating tissue degeneration when repeated. It’s a localized therapy that triggers the body’s natural healing, so systemic risks are minimal. The lack of significant adverse events holds true in osteoarthritis studies – for example, both meta-analyses in 2020 reported only minor complications like temporary pain and no significant differences in drop-out rates between ESWT and control groups.
Contraindications: Though safe for most people, shockwave therapy is not used in certain situations. It’s contraindicated to apply shockwaves over an area of active cancer, over open wounds or acute infections, or in patients with bleeding disorders who might bruise excessively. It’s also avoided directly over the torso of pregnant patients out of caution. These precautions are generally easy to manage – for hip OA, they rarely come into play except making sure there’s no local infection or tumor. A qualified provider will screen for these contraindications. Assuming those are clear, ESWT is considered very safe. Compared to surgical or pharmaceutical alternatives for osteoarthritis, shockwave’s risk profile is arguably one of the most favorable, which is a big reason patients and clinicians are excited about it as a treatment modality.
In summary, patients can feel confident that shockwave therapy for hip or knee OA carries minimal risk, aside from some discomfort during the procedure and short-lived soreness afterward. As always, it should be applied by a trained healthcare professional (physiotherapist, sports medicine physician, chiropractor, etc.) who can properly target the treatment and ensure it’s appropriate for the patient’s condition.
The Unpain Clinic – a leading shockwave therapy clinic known for its focus on regenerative treatments – has shared valuable insights through their podcast and YouTube channels about using shockwave for hip pain conditions. Founder Uran Berisha and his team emphasize assessing and treating the root causes of hip dysfunction, not just the symptoms. Here are a few key takeaways from Unpain Clinic’s content:
Holistic Approach to Hip Pain: In an episode of the Unpain Clinic Podcast devoted to hip pain, Berisha explains that hip problems often stem from years of muscle imbalances, old injuries, or poor movement patterns – not simply “age” or wear-and-tear. Shockwave therapy is used in conjunction with correcting those dysfunctions. The clinic’s philosophy is “we treat why it hurts, not just where it hurts”, meaning they look at the whole kinetic chain (lower back, core, gait, etc.) to find what’s overloading the hip. For instance, an old ankle sprain or a C-section scar can alter one’s biomechanics and contribute to hip joint stress. By releasing adhesions (with shockwave) and then retraining the muscles, they aim for lasting relief.
Shockwave’s Role – “True Healing”: Unpain Clinic practitioners often highlight that shockwave therapy triggers biological healing rather than providing a quick temporary fix. As mentioned earlier, Uran Berisha describes shockwave’s effect as stimulating real healing by breaking down adhesions, increasing local blood circulation, and inducing collagen production in damaged tissues. In a YouTube video on hip pain, he demonstrates how focused shockwaves to the hip region can free up scar tissue from prior surgeries (like hip replacements or abdominal surgeries) and restore muscle activation. The immediate result some patients feel is better mobility; the longer-term result is tissue regeneration. The clinic has shown cases of “instant” improvements in muscle strength or range after shockwave application post-hip replacement, for example, as proof of this neuromuscular activation effect. While results vary, these anecdotes align with research showing shockwaves promote angiogenesis (new blood vessels) and recruit growth factors to repair tendons and cartilage.
Real Patient Outcomes: Unpain’s content often shares patient stories. In one podcast, they mention that many clients who had been told they “need a hip replacement” were able to avoid surgery after addressing dysfunctions and getting shockwave therapy to heal the joint. They caution that this works best if degeneration is caught early – if you “catch it early, you can avoid unnecessary surgeries and reclaim full function”. Another blog article from January 2026 on hip bursitis (a common source of lateral hip pain) notes that approximately 75–80% of chronic hip bursitis sufferers get significant relief from shockwave therapy, especially when combined with exercise therapy. This matches the success rates seen in clinical studies for GTPS (trochanteric pain syndrome). The article also referenced a crossover trial where patients who failed to improve with exercise did improve after receiving shockwave, highlighting ESWT’s ability to jump-start recovery. Unpain Clinic’s practitioners have observed that by the end of a typical shockwave treatment series (usually ~3–6 sessions over a few weeks), most patients report significant pain reduction and better hip function, provided underlying issues are addressed too. And because shockwave’s effects are regenerative, these results “tend to hold” – patients remain pain-free as long as they maintain their exercises and healthy movement patterns.
Education and Expectations: Unpain Clinic also stresses educating patients that shockwave is not an instant magic cure, but a process. It works cumulatively: they often see noticeable changes after the first two sessions (e.g. improved sleep or reduced night pain), and “by the 4th or 5th session, we expect to see meaningful functional gains”, such as walking longer with less pain. Setting realistic expectations helps patients stick with the treatment and do their part (exercises, posture changes, etc.). The clinic’s experience is that if a patient isn’t responding as expected by mid-treatment, they revisit the assessment to adjust the plan (maybe targeting a different muscle group or adding a complementary therapy). This flexible, patient-specific approach is part of why their outcomes are positive.
In summary, the Unpain Clinic’s perspective reinforces what the scientific evidence suggests: shockwave therapy, especially true focused shockwave, is a cutting-edge modality that can significantly help with hip pain and dysfunction. By integrating it into a holistic treatment addressing muscle imbalances and scars, they achieve high success rates in conditions like hip OA, hip bursitis, and even post-surgical hip rehabilitation. Their public podcasts and videos serve to educate patients that shockwave is a powerful tool for pain relief and joint recovery – one that treats the cause (tissue damage and poor healing) rather than just the symptoms.
For individuals suffering from hip osteoarthritis, shockwave therapy (ESWT) is an emerging non-invasive treatment that shows considerable promise. In the last 5–10 years, clinical studies – including a pioneering 2022 RCT in hip OA – have demonstrated that shockwave treatment can reduce pain, improve joint function, and enhance quality of life in osteoarthritic joints. While direct research on hip OA is still sparse, evidence from knee OA and related hip conditions (like trochanteric bursitis) suggests that shockwaves promote longer-term healing of tissues, leading to sustained pain relief for many patients. Patients have experienced improvements in walking ability, strength, and day-to-day activities after a course of shockwave therapy, often allowing them to delay or avoid more invasive interventions.
Moreover, shockwave therapy is safe and well-tolerated – it avoids the risks of surgery and repeated steroid injections, and its side effects are generally limited to short-term soreness. No serious complications have been reported in the literature. Treatment protocols typically involve a series of weekly sessions (about 3–6 sessions, depending on severity), and improvements tend to accumulate with each treatment. It’s important to have qualified healthcare providers perform the therapy and tailor it to the patient’s needs, as optimal energy levels and targeting can influence outcomes.
Perhaps the most important insight is that shockwave therapy works best as part of a comprehensive approach. Combining ESWT with corrective exercises, strengthening, and addressing biomechanical issues yields the highest success rates in clinical practice. Shockwave essentially “unlocks” the healing potential by regenerating tissues and reducing pain, which then enables patients to rehab and rebuild better. Treatment response can vary – older patients or those with very advanced OA may need more time – but a substantial majority of patients can expect notable relief. As research on hip OA catches up, we anticipate seeing larger trials that will solidify guidelines on how to optimize shockwave therapy for hip joints specifically.
In conclusion, shockwave therapy for hip osteoarthritis is a promising and innovative modality that is gaining support from both scientific evidence and clinical practice. It offers hope for those who have exhausted conventional treatments yet still struggle with hip pain and limited function. By focusing on healing the root causes of pain (damaged bone, cartilage, tendons, and poor blood flow), ESWT stands out as a therapy that not only eases symptoms but also improves the underlying health of the joint. For patients and healthcare providers seeking an effective, low-risk treatment to manage hip OA pain and improve quality of life, shockwave therapy is certainly an option worth considering – with the latest studies indicating real benefits and the potential to “reset” a degenerating hip back toward recovery.
1. Şah, V. (2023). J. Pers. Med. – First RCT of ESWT in hip OA: focused vs radial vs sham outcomes.
2. Avendaño-Coy, J. et al. (2020). Int. J. Surgery 82:64–75 – Meta-analysis of ESWT in knee OA (pain, function improved).
3. Chen, L. et al. (2020). Biomed Res. Int. 2020:1907821 – Systematic review of ESWT in OA vs various treatments.
4. Wang, Y-C. et al. (2020). Pain Med. 21(4):822–835 – Meta-analysis: ESWT efficacy up to 12 months in knee OA.
5. Zhong, Z. et al. (2019). Arch Phys Med Rehabil. 100(9):1695–1702 – RCT: low-dose ESWT vs sham in knee OA (12-week outcomes).
6. Pasin, T. et al. (2025). J. Clin. Med. 14(3): – RCT: ESWT vs LLLT vs PEMF in knee OA (short-term QoL and pain results).
7. Unpain Clinic Podcast Episode 5 (2023): “The Hidden Connection Between Your Hips and the Rest of Your Body.” – Discusses hip dysfunction causes and shockwave therapy approach.
8. Unpain Clinic Blog (Jan 20, 2026): “Shockwave Therapy for Hip Bursitis: A Non-Surgical Solution…” – Reviews research and notes ~75% success in chronic hip pain with ESWT.
9. Unpain Clinic YouTube Shorts (2023): “Shockwave Therapy for Hip Pain – Real Results.” – Demonstration and patient testimony of hip pain relief with focused shockwave.
